CriteriaInfectious diseases
Severity and treatment of a first C. difficile infection episode (IDSA/SHEA)
Classifies a first Clostridioides difficile infection episode as non-severe, severe or fulminant and suggests treatment per the IDSA/SHEA guideline.
Updated 30 October 2026
When to use it
Adults with confirmed C. difficile infection in a first episode (not recurrences).
Warning
Adjust doses and choice to local availability, renal function and interactions; recurrences follow a different scheme.
What it needs
- White blood cell count
- Serum creatinine
- Signs of fulminant disease
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Non-severe: fidaxomicin 200 mg every 12 h for 10 days (preferred) or oral vancomycin 125 mg every 6 h for 10 days |
| 2 | Severe (WBC ≥ 15 × 10⁹/L or creatinine > 1.5 mg/dL): fidaxomicin 200 mg every 12 h or oral vancomycin 125 mg every 6 h, 10 days |
| ≥ 3 | Fulminant: vancomycin 500 mg every 6 h orally or by tube + IV metronidazole 500 mg every 8 h; surgical review |
Practical tip
Stop the inciting antibiotic if possible and avoid antiperistaltic agents in the acute phase.
2 more practical tips in the app.
Reference
- McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the IDSA and SHEA. Clin Infect Dis. 2018;66(7):e1-e48.
- Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the IDSA and SHEA: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
